on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer.
NEWS: Over 500 race to raise awareness, funds for traumatic disease: '5K to Fight Histio'
More than 400 runners in New York City were joined by an additional 100 virtual participants in several countries to raise awareness of hemophagocytic lymphohistiocytosis, or HLH. Novimmune was a sponsor of this year's 5K event. (27 JUL 2015)
NEWS: New drug begins testing as first-line treatment for fatal childhood disease
International clinical trial for NI-0501 in hemophagocytic lymphohistiocytosis implements protocol amendment across multiple investigational sites in the US and Europe. (16 MAR 2015)